Results 41 to 50 of about 4,535 (170)

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review

Advances in Respiratory Medicine
Nirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study

BMC Medicine
Background Paxlovid has been shown to be effective in reducing mortality and hospitalization rates in patients with coronavirus disease 2019 (COVID-19).
Weijie Wang, Yu-Hsun Wang, Ching-Hua Huang, Tsung-Hsueh Hsieh, Gema Hernández Ibarburu, James Cheng-Chung Wei   +5 more
doaj   +1 more source

Paxlovid: Mechanism of Action, Synthesis, and In Silico Study

BioMed Research International, 2022
In this work, the discovery and description of PF‐07321332, a major bioavailable oral SARS‐CoV‐2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent selection of off‐target and in vivo immune profiles are reported. Various drugs and novel compound candidates for the treatment of the COVID‐19 pandemic have been developed.
Mahrokh Marzi, Mohammad Kazem Vakil, Maryam Bahmanyar, Elham Zarenezhad   +3 more
openaire   +2 more sources

Exploration of Nirmatrelvir Derivatives as Optimized SARS‐CoV‐2 Antivirals

ChemMedChem, Volume 21, Issue 15, 14 August 2026.
Structure‐guided optimization of nirmatrelvir identifies aldehyde and dichloroacetamide warheads and a potency‐enhancing S4 thioamide. Crystal structures reveal an S2 rearrangement extending toward Cys44, suggesting a new covalent‐design opportunity.
Yugendar R. Alugubelli, Veerabhadra R. Vulupala, Kai S. Yang, Kaustav Khatua, Lauren R. Blankenship, Sathish Kumar, Demonta Coleman, Xuejiao Guo, Zhi Zachery Geng, Chia‐Chuan D. Cho, Banumathi Sankaran, Benjamin W. Neuman, Shiqing Xu, Wenshe Ray Liu   +13 more
wiley   +1 more source

Population-Based Propensity Score-Matched Analysis of Paxlovid and Molnupiravir Effectiveness in High-Risk COVID-19 Patients

International Journal of Infectious Diseases
Introduction: COVID-19 poses a severe threat to high-risk populations, such as the elderly and those with incomplete vaccination. Despite the availability of treatments like Paxlovid and Molnupiravir, their relative effectiveness in preventing severe ...
Dr Yi-hsuan Chen, Dr Cheng-Yi Lee, Dr Hao-Yuan Cheng, Mr. Yu-Neng Cheuh, Mr. Hung-Wei Kuo   +4 more
doaj   +1 more source

Survival benefit and safety evaluation of probiotic supplementation in omicron‐infected patients: Real‐world evidence from a multicenter 12,615‐patient cohort

VIEW, Volume 7, Issue 4, August 2026.
Probiotic supplements have shown benefits in reducing all‐cause mortality among hospitalized patients with SARS‐CoV‐2 infection. Patients with severe illness or without antiviral treatment were more likely to use probiotic supplements. Probiotic supplements may be a promising adjunctive therapy for SARS‐CoV‐2 infection.
Mengzhao Yang, Shanshuo Liu, Junyi Sun, Fuwei Wang, Guangyun Zhu, Xinjun Hu, Guowu Qian, Yiqiang Yuan, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Zujiang Yu, Zhigang Ren   +14 more
wiley   +1 more source

Paxlovid reduces the 28-day mortality of patients with COVID-19: a retrospective cohort study

BMC Infectious Diseases
Purpose In this study, we aim to explore the efficacy of paxlovid on reducing mortality of COVID-19 patients in clinical setting, especially whether paxlovid modifies the risk of death in these severe and critical patients.
Kaican Zong, Li Xu, Chun Luo, Chen Luo, Bin Liu, Jiacheng Chen, Huizi Wu, Zhiqiang Liu, Rongjuan Zhuang, Shuliang Guo   +9 more
doaj   +1 more source

Sphinganine‐phosphate prevents influenza infection via promoting CD8+ T cells proliferation and activation

VIEW, Volume 7, Issue 4, August 2026.
This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...
Zhongwen Hu, Guiling Yan, Junhong Li, Yuan Yuan, Hong Zhang, Yuchao Zhong, Yuanyuan Peng, Wenjia Zhang, Xiaoyan Su, Changchun Niu, Yang Luo   +10 more
wiley   +1 more source

Should Paxlovid be prescribed for patients with severe COVID‐19 in the late course of infection? A case report

Medicine Advances, 2023
The infection of the coronavirus disease 2019 (COVID‐19) is often accompanied by pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in patients with mild and normal pneumonia within 5 days from the symptom onset. Herein, we
Qiang Li, Yibo He, Jin Liu, Xiaozhao Lu, Ziyou Zhou, Yu Kang, Wanying Wu, Jielan Wu, Feng Wang, Yinghao Sun, Wei Wang, Chengyi Hui, Wenting Wei, Miaoyun Wen, Jingjing Chen, Yong Liu   +15 more
doaj   +1 more source